FDA Listening Session: Early Onset FSHD

Early-onset FSHD is a severe, relentlessly progressive form of FSHD which profoundly affects emotional well-being, child development, family life, independence, and quality of life.

Cover page of the Early Onset FSHD summary of their July 1, 2026 Patient Listening Session with the FDA. 3 white boxes with black text sit in front of a light orange background.

Box 1: Early-Onset Facioscapulohumeral Muscular Dystrophy
(FSHD) Patient Listening Session Summary

Box 2: Every Age. Every Stage. A Cure For All.

Box 3: Prepared by:
FSHD Cure Initiative
In partnership with FSHD Society and Solve FSHD
Patient Listening Session:
July 1, 2026
Date of Report: August 31, 2026However, individuals living with Early Onset FSHD face barriers in accessing clinical trials and competent care as they adapt to an ongoing cycle of muscle and ability loss. On July 1, 2026, the Early Onset community helped the FDA understand the FSHD disease spectrum and the life-long impact of FSHD. Thank you to the courageous youth and caregivers who spoke honestly about FSHD’s relentless progression and the need for a cure accessible to children and the non-ambulatory.

Read the report